ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,277, issued on Aug. 5, was assigned to DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL Co. LTD. (Zhejiang, China).
"SGLTS/DPP4 inhibitor and application thereof" was invented by Qinghua Mao (Shanghai), Tao Yu (Shanghai), Yi Li (Shanghai), Chengde Wu (Shanghai) and Shuhui Chen (Shanghai).
According to the abstract* released by the U.S. Patent & Trademark Office: "A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved."
The patent was filed on July 24, 2020, unde...